Results of the Etoricoxib Versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial

Total Page:16

File Type:pdf, Size:1020Kb

Results of the Etoricoxib Versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial Gastrointestinal Side Effects of Etoricoxib in Patients with Osteoarthritis: Results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial HERBERT S.B. BARAF, CARLOS FUENTEALBA, MARIA GREENWALD, JAN BRZEZICKI, KATHERINE O’BRIEN, BETH SOFFER, ADAM POLIS, STEVEN BIRD, AMARJOT KAUR, and SEAN P. CURTIS, for the EDGE Study Group ABSTRACT. Objective. To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA). Methods. In total, 7111 patients (mean age 64 yrs) diagnosed with OA were enrolled in a randomized, double-blind trial. Patients received etoricoxib 90 mg qd (n = 3593) or diclofenac sodium 50 mg tid (n = 3518). Gastroprotective agents and low-dose aspirin were prescribed per treatment guidelines. The primary endpoint was the cumulative rate of discontinuations due to clinical and laboratory GI adverse experiences (AE). General safety was assessed, including adjudication of thrombotic cardiovascular (CV) safety data. Efficacy was evaluated using the least-square (LS) mean change from baseline patient global assessment of disease status (PGADS; 0–4 point scale). Results. Mean (SD, maximum) duration of treatment was 9.3 (4.4, 16.5) and 8.9 (4.5, 16.6) months in the etoricoxib and diclofenac groups, respectively. The cumulative discontinuation rate due to GI AE was significantly lower with etoricoxib than diclofenac [9.4 vs 19.2 events per 100 patient-years (PY), respectively; hazard ratio (HR) 0.50 (95% CI 0.43, 0.58; p < 0.001). Rates of thrombotic CV events were similar with etoricoxib and diclofenac [1.25 vs 1.15 events per 100 PY, respectively; HR 1.07 (95% CI 0.65, 1.74)]. The incidence of patients who discontinued due to hypertension-related AE was significantly higher with etoricoxib compared to diclofenac (2.3% vs 0.7%; p < 0.001), although few AE were severe (3 etoricoxib, 1 diclofenac). Etoricoxib and diclofenac treatment resulted in similar improvements in PGADS from baseline of –0.78 (95% CI –0.80, –0.75) and –0.75 (95% CI –0.77, –0.72), respectively. Conclusion. Treatment with etoricoxib 90 mg was associated with significantly better GI tolerability compared to diclofenac in this population of patients with OA. Etoricoxib 90 mg, a dose 50% higher than indicated for OA, resulted in more discontinuations due to hypertension-related AE. (J Rheumatol 2007;34:408–20) Key Indexing Terms: ETORICOXIB DICLOFENAC OSTEOARTHRITIS GASTROINTESTINAL TOLERABILITY Osteoarthritis (OA) is one of the most common disabilities year 20201. The primary objective of treatment for patients present in the elderly population and is projected to be the with OA is to manage symptoms, including pain and inflam- fourth leading cause of disability on a worldwide basis by the mation, and to improve quality of life2,3. For patients who From the Center for Rheumatology and Bone Research, Wheaton, Merck & Co., Ortho-McNeill, Pfizer, Procter and Gamble, Roche, Wyeth, Maryland, USA; Hospital San Borja Arriarán, Santiago, Chile; Desert and Zelos Therapeutics. J. Brzezicki has received research support from Medical Advances, Palm Desert, California, USA; Oddzial Reumatologii and served as a speaker and consultant for Merck & Co. K. O’Brien, – Wojewodzki Szpital Zespolony, Elblag, Poland; and Merck & Co., Inc., B. Soffer, A. Polis, S. Bird, A. Kaur, and S.P. Curtis are employees of West Point, Pennsylvania, and Rahway, New Jersey, USA. Merck & Co. and own stock and/or hold stock options in the Company. Supported by Merck & Co., Inc., Whitehouse Station, NJ, USA. Clinical H.S.B. Baraf, MD, The Center for Rheumatology and Bone Research; study protocol registered at http://www.clinicaltrials.gov/ct/show/ C. Fuentealba, MD, Hospital San Borja Arriarán; M. Greenwald, MD, NCT00092703. H.S.B. Baraf serves as a consultant for Merck & Co. and Desert Medical Advances; J. Brzezicki, MD, Oddzial Reumatologii– Savient Pharmaceuticals. He has received research grant support from Wojewodzki Szpital Zespolony; K. O’Brien, BS; B. Soffer, BA, Med, RA; Merck & Co., Pfizer, Amgen, Centocor, Abbott Laboratories, TAP A. Polis, MA; S. Bird, MS; A. Kaur, PhD; S.P. Curtis, MD, Merck & Co., Pharmaceutical Products, GlaxoSmithKline, Sanofi-Aventis, and Savient Inc. Pharmaceuticals. He has served as a speaker for Merck & Co., Pfizer, Address reprint requests to Dr. H.S.B. Baraf, The Center for Amgen, Centocor, Abbott, and TAP Pharmaceutical Products. C. Rheumatology and Bone Research, 2730 University Boulevard West, Suite Fuentealba has received research support from and served as a speaker 306, Wheaton, MD 20902, USA, E-mail: [email protected] for Merck & Co. M. Greenwald has received research support from Abbott Laboratories, Allelix, Amgen, Sanofi-Aventis, Biogen Idec, Bristol-Myers Accepted for publication August 23, 2006. Squibb, Boehringer Mannheim, Genentech, GlaxoSmithKline, Eli Lilly, Personal non-commercial use only. The Journal of Rheumatology Copyright © 2007. All rights reserved. 408 The Journal of Rheumatology 2007; 34:2 Downloaded on September 30, 2021 from www.jrheum.org require effective pain and symptom relief, nonsteroidal antiin- malignancy within the past 5 years that had not been successfully treated; flammatory drugs (NSAID) are often prescribed. Lack of effi- required therapy with warfarin, heparin, high-dose aspirin (> 100 mg/day), nonstudy NSAID or coxib, or the combination of ticlopidine or clopidogrel cacy is the leading cause for switching treatment to other 4 plus low-dose aspirin; or allergy or hypersensitivity to aspirin, other tradi- members of the NSAID class . The use of traditional NSAID tional NSAID, or coxibs. In addition, patients who used H2-receptor antago- can be limited due to their inherent toxicity to the upper and nists, antacids, or proton pump inhibitors at prescription or over-the-counter lower gastrointestinal (GI) tract5,6. Specifically, use of tradi- doses for more than 4 consecutive days within 1 month prior to the screening tional NSAID is associated with upper GI intolerance (often visit were excluded. Patients were also excluded who used misoprostol or sucralfate within 3 days prior to study start. characterized under the general term of dyspepsia), which is Study design. This was a randomized, double-blind, active-comparator-con- not necessarily related to GI mucosal injury or serious upper 7-9 trolled, multicenter study (Sponsor protocol number 061) to compare the GI GI events (i.e., perforations, ulcers, or bleeds) . Dyspeptic tolerability of etoricoxib and diclofenac. The EDGE trial is a component of symptoms can occur in a significant proportion (~25%) of the larger MEDAL Program, which consists of 3 studies: EDGE; EDGE II 19 patients being treated with traditional NSAID7. Patients expe- (NCT00250445); and MEDAL (NCT00092742) . The trial was designed to riencing GI symptoms may be prescribed gastroprotective run for about 18 months with an enrollment period of about 5 months. Based on the predefined end-of-study period for all patients and time between agents (GPA) to alleviate their symptoms, or may discontinue 10,11 screening and enrollment, the maximum duration of treatment for a patient and/or switch treatment . Hepatotoxicity due to NSAID could range from 11 to 16 months. therapy occurs at a much lower rate than dyspeptic symptoms, Following screening, patients discontinued their prestudy OA medication but is also associated with treatment switching12. and returned to the clinical research center within 2 to 10 days. Patients who Selective inhibitors of COX-2 (coxibs) such as etoricoxib completed this prestudy washout period were stratified according to low-dose aspirin use and randomized using a computer-generated randomization sched- were developed to reduce the risk of GI adverse experiences ule, in a 1:1 ratio, to etoricoxib 90 mg qd or diclofenac sodium 50 mg tid. 13,14 (AE) . A combined analysis of 9 randomized, double- Study medication was supplied in 2 coded study bottles, labeled bottle A (con- blind, efficacy studies of the coxib etoricoxib, across its devel- taining etoricoxib 90 mg tablets or matching placebo) and bottle B (contain- opment program, suggested reduced rates of discontinuation ing diclofenac sodium 50 mg tablets or matching placebo). Patients were instructed to take one tablet in the morning from bottles A and B and one of etoricoxib or of GPA use due to dyspeptic symptoms dur- tablet in the afternoon and evening from bottle B. Acetaminophen (up to 2600 ing the first 6 months of use compared to traditional mg per day) served as rescue pain medication. If acetaminophen failed, non- 15,16 NSAID . To further evaluate this, our current study was aspirin, non-NSAID analgesic alternatives (e.g., narcotic analgesic) could be designed with the primary objective of evaluating the GI “tol- taken for a maximum of 3 doses per day for up to 7 days per month. erability” of etoricoxib 90 mg qd compared to diclofenac 50 Safety and efficacy data were collected during clinic visits (screening, randomization, and at 1, 4, 8, and 12 months of therapy, and at end of study). mg tid, in patients with OA, using the primary endpoint of The investigators identified and evaluated AE based on patient reports, phys- treatment discontinuations due to clinical and laboratory GI ical examination, and laboratory assessments. Telephone contacts to monitor AE. GI tolerability was assessed by determining the rates of compliance and facilitate patient retention occurred monthly between visits treatment discontinuation arising from the development of the (Months 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, and 16 for patients remaining in the study). Pill counts furnished a measure of compliance. Patients contacted GI signs, symptoms, or laboratory abnormalities associated the investigator if they desired to discontinue treatment, or an investigator with NSAID use. The trial was not designed to formally test could recommend discontinuation. Study sites contacted patients who dis- treatment differences related to GI safety (i.e., rates of perfo- continued early by telephone every 4 months, at 12 months, and at the prede- rations, ulcers, or bleeds).
Recommended publications
  • SBARD – Lithium Nsaids
    SBARD in Relation to Potentially Dangerous Interaction Between Lithium and Anti- Inflammatory Drugs A number of medication incidents have been reported recently concerning the prescribing and administration of non-steroidal anti-inflammatory drugs S (NSAIDs) to patients on lithium. Situation Co-administration of a NSAID or cyclo-oxygenase (COX)-2 inhibitor, with lithium increases the risk of lithium toxicity In the last 6 months (Oct.11-Mar.12) there have been 3 Datix incident reports concerning the prescription of a NSAID for in-patients stabilised on lithium. B In each case the NSAID was prescribed “as required”, which increases the risk Background of lithium toxicity due to irregular administration with no increase in lithium monitoring frequency. NSAIDs and COX-2 inhibitors reduce the renal excretion of lithium via their A action on renal prostaglandins, resulting in increased plasma lithium levels. The level of increase is unpredictable (from 10-400%), and the onset of effect is Assessment variable (few days to several months). Risks are increased in patients with impaired renal function, renal artery stenosis or heart failure, and who are dehydrated or on a low salt diet. Co-prescription of NSAIDs or COX-2 inhibitors with lithium is not an absolute R contra-indication, but should be undertaken with extreme caution and only Recommendation when clinically essential. The risk of lithium toxicity is increased with “as required” or intermittent dosing (e.g. when used for menorrhagia), when the effects are less predictable – regular dosing
    [Show full text]
  • Spondyloarthritis: NMA on Pain Outcome RR111467
    NICE CGTSU Spondyloarthritis: NMA on Pain Outcome RR111467 Spondyloarthritis: NMA on pain outcome CGTSU, Bristol (Edna Keeney and Sofia Dias) The purpose of this analysis was to estimate the comparative effectiveness of the following pharmacological interventions for management of pain associated with axial spondyloarthritis: 1. Indomethacin (Reference) 2. Diclofenac 3. Sulindac 4. Fenoprofen 5. Ketoprofen 6. Flurbiprofen 7. Tenoxicam 8. Piroxicam 9. Celecoxib 200mg 10. Celecoxib 400mg 11. Aceclofenac 12. Naproxen 13. Enteric coated Naproxen 14. Etoricoxib 15. Tolfenamic acid 16. Meloxicam 15mg 17. Placebo 23 studies were included in the analyses. The network diagram is shown in Figure 1. Edna Keeney 1 13/10/2015 NICE CGTSU Spondyloarthritis: NMA on Pain Outcome RR111467 Figure 1. Network Diagram for pain outcome Pain Indomethacin Placebo Diclofenac Meloxicam 15mg Sulindac Tolfenamic acid Fenoprofen Etoricoxib Ketoprofen Enteric coated naproxen Flurbiprofen Naproxen Tenoxicam Piroxicam Aceclofenac Celecoxib 400mg Celecoxib 200mg METHODS In order to take all trial information into consideration, Mixed Treatment Comparison meta-analytic techniques, also termed Network meta-analysis (NMA), were employed. NMA is a generalization of standard pairwise meta-analysis for A versus B trials, to data structures that include, for example, A versus B, B versus C, and A versus C trials.1-3 A basic assumption of NMA methods is that direct and indirect evidence estimate the same parameter, that is, the relative effect between A and B measured directly
    [Show full text]
  • Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective Nsaids, and Acetaminophen in Osteoarthritis: a Mixed Treatment Comparison W.B
    6 The Open Rheumatology Journal, 2012, 6, 6-20 Open Access Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison W.B. Stam1, J.P. Jansen2 and S.D. Taylor*,3 1Mapi Group, Houten, The Netherlands 2Mapi Group, Boston, MA, USA 3Merck & Co., Inc., Whitehouse Station, NJ, USA Abstract: Objective: To compare the efficacy of etoricoxib, lumiracoxib, celecoxib, non-selective (ns) NSAIDs and acetaminophen in the treatment of osteoarthritis (OA) Methods: Randomized placebo controlled trials investigating the effects of acetaminophen 4000mg, diclofenac 150mg, naproxen 1000mg, ibuprofen 2400mg, celecoxib 100-400mg, lumiracoxib 100-400mg, and etoricoxib 30-60mg with treatment duration of at least two weeks were identified with a systematic literature search. The endpoints of interest were pain, physical function and patient global assessment of disease status (PGADS). Pain and physical function reported on different scales (VAS or LIKERT) were translated into effect sizes (ES). An ES 0.2 - 0.5 was defined as a “small” treatment effect, whereas ES of 0.5 – 0.8 and > 0.8 were defined as “moderate” and “large”, respectively. A negative effect indicated superior effects of the treatment group compared to the control group. Results of all trials were analyzed simultaneously with a Bayesian mixed treatment comparison. Results: There is a >95% probability that etoricoxib (30 or 60mg) shows the greatest improvement in pain and physical function of all interventions compared. ESs of etoricoxib 30mg relative to placebo, celecoxib 200mg, ibuprofen 2400mg, and diclofenac 150mg were -0.66 (95% Credible Interval -0.83; -0.49), -0.32 (-0.50; -0.14), -0.25 (-0.53; 0.03), and -0.17 (-0.41; 0.08), respectively.
    [Show full text]
  • Analgesic Effect of Etoricoxib Compared to Ibuprofen on Post Endodontic Pain
    Analgesic Effect of Etoricoxib Compared to Ibuprofen on Post Endodontic Pain Zahra-Sadat Madani1, Ali Akbar Moghadamnia2, Ali Panahi3, Arash Poorsattar Bejeh Mir4 1Department of Endodontics, Dentistry School, Babol University of Medical Sciences, Babol, Mazandaran Province, Iran. 2Department of Pharmacology, School of Medicine, Babol University of Medical Sciences, Babol, Mazandaran Province, Iran. 3General Dentist, Private Practice, Mazandaran Province, Babol, Iran. 4Dental Materials Research Center, Dentistry School, Babol University of Medical Sciences, Babol, Mazandaran Province, Iran. Abstract Aims: Etoricoxib is a second-generation selective COX-2 inhibitor. There are a few researches investigating analgesic effect of Etoricoxib in dentistry. Methods: This randomized, double-blind, active-control study included sixty patients with clinical pulpal diagnosis of necrosis of the first mandibular molar and an associated periapical radiolucency who experienced severe pain (more than 60 out of 100 in scale of Visual Analog Scale (VAS). The patients were equally randomized into four groups, who received 60 mg etoricoxib (group 1), 90 mg etoricoxib (group 2), 120 mg etoricoxib (group 3), and 400 mg ibuprofen (group 4). All patients randomly received a single dose of the drug after the first session of the root canal therapy. Using VAS, the severity of pain was recorded 2, 4, 6, 12, 24, 48, and 72 hours after the drug was administered. Results: Changing trends of pain over the time was significant for all groups (P=0.003). In addition, there was not a significant difference between various study arms (P=0.146). Conclusion: The results showed that ibuprofen had a comparable effect with various dosage of etoricoxib and may remain as the choice analgesic for dental pulpal pain.
    [Show full text]
  • Safety of Etoricoxib in Patients with Reactions to Nsaids
    ORIGINAL ARTICLE Safety of Etoricoxib in Patients With Reactions to NSAIDs O Quercia, F Emiliani, FG Foschi, GF Stefanini Allergology High Specialty Unit, General Medicine, Faenza Hospital, AUSL Ravenna, Italy ■ Abstract Background: Adverse reactions to nonsteroidal anti-infl ammatory drugs (NSAIDs) are a frequently reported problem due to the fact that these molecules are often used for control of pain and infl ammation. Although the use of selective inhibitors of cyclooxygenase (COX) 2 helps to prevent some of these adverse reactions, they can have cardiac side effects when taken for prolonged periods. Here we report the safety and tolerability of etoricoxib, a selective COX-2 inhibitor with fewer cardiovascular effects, in patients with adverse reactions to NSAIDs. Patients and methods: We performed placebo-controlled oral challenge with etoricoxib in 65 patients with previous adverse reactions to NSAIDs: 13 to salicylates, 18 to arylpropionic acids, 10 to arylacetic acid, 12 to oxicam and derivates, 8 to pyrazolones, and 4 to acetaminophen (paracetamol). The reported symptoms were urticaria or angioedema in 69%, rhinitis in 3%, and 1 case of anaphylactic shock (1.5%). The challenge was done using the placebo on the fi rst day, half dosage of etoricoxib (45 mg) on the second day, and the therapeutic dose of 90 mg on the third day. The challenge was done in the outpatient department of the hospital and the subjects were monitored for a further 4 to 6 hours after challenge. Results: Oral challenge with etoricoxib was well tolerated in 97% of the patients. Only 2 systemic reactions were reported during the challenge test.
    [Show full text]
  • Etoricoxib 30Mg, 60Mg, 90Mg and 120Mg Film-Coated Tablets
    Package leaflet: Information for the user Etoricoxib 30mg, 60mg, 90mg and 120mg Film-coated Tablets etoricoxib Read all of this leaflet carefully before you start • you have diabetes, high cholesterol, or are a smoker. These taking this medicine because it contains important can increase your risk of heart disease. information for you. • you are a woman trying to become pregnant. • Keep this leaflet. You may need to read it again. • you are over 65 years of age. • If you have any further questions, ask your doctor or If you are not sure if any of the above apply to you, talk to your pharmacist. doctor before taking etoricoxib to see if this medicine is • This medicine has been prescribed for you only. Do not pass suitable for you. it on to others. It may harm them, even if their signs of illness are the same as yours. Etoricoxib works equally well in older and younger adult • If you get any side effects, talk to your doctor or patients. If you are over 65 years of age, your doctor will want pharmacist. This includes any possible side effects not to appropriately keep a check on you. No dosage adjustment is listed in this leaflet. See section 4. necessary for patients over 65 years of age. • The full name of this medicine is Etoricoxib 30mg, 60mg, 90mg and 120mg Film-coated Tablets but within this Children and adolescents Do not give this medicine to children and adolescents under 16 leaflet it will be referred to as Etoricoxib Tablets. years of age. What is in this leaflet Other medicines and Etoricoxib Tablets 1 What Etoricoxib Tablets are and what they are Tell your doctor or pharmacist if you are taking, have recently used for taken or might take any other medicines, including medicines 2 What you need to know before you take obtained without a prescription.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Inflammatory Drugs
    Solubility of Nonsteroidal Anti- diflunisal, etoricoxib, fenbufen, fentiazac, flufenamic inflammatory Drugs (NSAIDs) in acid, flurbiprofen, ibuprofen, indomethacin, ketopro- Neat Organic Solvents and Organic fen, ketorolac, lornoxicam, mefenamic acid, melox- Solvent Mixtures iam, nabumetone, naproxen, niflumic acid, nimesulide, phenylbutazone, piroxicam, rofecoxib, sodium diclof- William E. Acree enac, sodium ibuprofen, sodium naproxen, sodium J. Phys. Chem. Ref. Data 43, 023102 (2014) salicylate, tenoxicam, tolfenamic acid, and valdecoxib. IUPAC-NIST Solubility Data Series, Volume 102 http://dx.doi.org/10.1063/1.4869683 This IUPAC-NIST Solubility Data Series volume reviews experimentally determined solubility data for 33 non- To access recent volumes in the Solubility Data Series, visit http://jpcrd.aip.org/ and steroidal anti-inflammatory drugs (NSAIDs) dissolved search IUPAC-NIST Solubility Data Series in neat organic solvents and well-defined binary and ternary organic solvent mixtures retrieved from the published chemical and pharmaceutical litera- ture covering the period from 1980 to the beginning of 2014. Except for aspirin (2-acetoxybenzoic acid) and salicylic acid (2-hydroxybenzoic acid), very little Provisional Recommendations physical and chemical property data are available Provisional Recommendations are drafts of IUPAC in the published literature for NSAIDs prior to 1980. recommendations on terminology, nomenclature, and Solubility data are compiled and critically reviewed symbols made widely available to allow interested
    [Show full text]
  • Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
    Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies
    [Show full text]
  • PRODUCT INFORMATION Etodolac Item No
    PRODUCT INFORMATION Etodolac Item No. 20833 CAS Registry No.: 41340-25-4 Formal Name: 1,8-diethyl-1,3,4,9-tetrahydro- pyrano[3,4-b]indole-1-acetic acid Synonyms: AY 24236, (±)-Etodolac, NIH 9918, H OH NSC 282126 N O O MF: C17H21NO3 FW: 287.4 Purity: ≥98% UV/Vis.: λmax: 224, 273 nm Supplied as: A crystalline solid Storage: Room temperature Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Etodolac is supplied as a crystalline solid. A stock solution may be made by dissolving the etodolac in the solvent of choice. Etodolac is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of etodolac in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of etodolac can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of etodolac in PBS, pH 7.2, is approximately 0.25 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits both COX isoforms in vitro, with modest selectivity for COX-2 (IC50s = 12 µM for COX-1 and 2.2 µM for COX-2 in a human whole blood assay).1 Experimental evidence suggests that etodolac may have favorable tissue pharmacokinetics resulting in further COX-2 selectivity, indicated by favorable reduction in anti-inflammatory action with diminished gastric side effects.2,3 References 1.
    [Show full text]
  • Steroidal Anti-Inflammatory Drugs (Nsaids) in Palliative Care
    GUIDELINES FOR THE USE OF NON- STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN PALLIATIVE CARE 2 9.1 GENERAL PRINCIPLES Non-steroidal anti-inflammatory drugs (NSAIDs) consist of a heterogenous group 1 of compounds that can be subdivided by virtue of their pharmacology: − Non-selective NSAIDs inhibit both COX-1 and COX-2 receptors e.g. ibuprofen, naproxen. − COX-2 selective NSAIDs display some selectivity for COX-2 receptors but this diminishes as the dose increases e.g. etodolac, meloxicam. − COX-2 inhibitors specifically inhibit COX-2 receptors at therapeutic doses whilst being COX-1 sparing e.g. celecoxib, etoricoxib. All NSAIDs have significant cardiovascular and gastrointestinal toxicity. 2 Consider whether alternative treatment would be appropriate (e.g. topical NSAIDs, paracetamol, tramadol). 1 3 Prescribe the lowest effective dose of NSAID for the shortest time necessary. 29.2 GUIDELINES 29.2.1 Cardiovascular risk and NSAID prescribing COX-2 inhibitors are contraindicated for use in patients with established ischaemic heart disease and / or cerebrovascular disease, and also in patients with peripheral arterial disease. 4 [Level 1] Despite conflicting evidence, non-selective NSAIDs and COX-2 selective NSAIDs are currently licensed for use in these groups of patients, although they should be used with caution. 1 [Level 4] 29.2.2 Renal dysfunction and NSAID prescribing Renal function should be assessed prior to the introduction of a NSAID and within 7 days of starting treatment or increasing the dose. 5, 6 [Level 4] Care is required when prescribing NSAIDs for patients with heart failure, ascites or impaired renal function, particularly those who are dehydrated or have a low effective circulating volume.
    [Show full text]
  • Etoricoxib (Arcoxia®▼)
    VERDICT & SUMMARY Etoricoxib (Arcoxia®▼) For the treatment of osteoarthritis, rheumatoid arthritis and acute gout Committee’s Verdict: CATEGORY A (Q3) BNF: 10.1.1 Etoricoxib is suitable for prescribing in primary care. Prescribers should bear in mind the warnings from the European Medicines Agency about cardiovascular safety of all the COX-II selective inhibitors, and follow the advice from the Committee for Safety on Medicines regarding their use. Category A: suitable for prescribing in primary care Q rating: The evidence for the efficacy and safety of etoricoxib was Q2 Q1 considered to be relatively strong, based on 13 randomised controlled trials higher place higher place weaker evidence stronger evidence comparing etoricoxib with placebo and other non-steroidal anti-inflammatory drugs (NSAIDs). The lack of evidence for cardiovascular safety and limitations for use only in patients at “high risk” of gastrointestinal events (NICE guidance) give it a low place in therapy. Q4 Q3 lower place lower place The Q rating relates to the drug’s position on the effectiveness indicator grid. weaker evidence stronger evidence The strength of the evidence is determined by the quality and quantity of studies that show significant efficacy of the drug compared with placebo or alternative Place therapy in primary care in therapy. Its place in therapy in primary care takes into account safety and practical Strength of evidence for efficacy aspects of using the drug in primary care, alternative options, relevant NICE guidance, and the need for secondary care input. MTRAC reviewed this drug because of concerns about the cardiovascular safety of COX-II selective inhibitors.
    [Show full text]